Top

Published in:

01-12-2008 | NON-THEMATIC REVIEW

Cell cycle control and adhesion signaling pathways in the development of metastatic melanoma

Authors: A. V. Danilov, O. V. Danilova, B. T. Huber

Published in: Cancer and Metastasis Reviews | Issue 4/2008

Abstract

Metastatic melanoma is a fatal malignancy which is remarkably resistant to treatment. It is not entirely clear what determines transition from primary local to metastatic melanoma. Recent gene profiling studies shed light onto the complexity of pathogenesis of melanoma progression. An interaction between cell cycle signaling, adhesion pathways and epithelial–mesenchimal transition program appears to be critical in the development of metastatic disease. An isolated deregulation of either of those pathways may not be sufficient to initiate tumor evolution towards an aggressive phenotype. Here we review how they act in concert to make such a transition possible.

Clark, W. H. (1991). Tumour progression and the nature of cancer. British Journal of Cancer, 64, 631–644.PubMed

Clark Jr., W. H., Elder, D. E., Guerry, D., Epstein, M. N., Greene, M. H., & Van Horn, M. (1984). A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Human Pathology, 15, 1147–1165.PubMedCrossRef

Breslow, A. (1970). Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Annals of Surgery, 172, 902–908.PubMedCrossRef

Kuehnl-Petzoldt, C., & Fischer, S. (1987). Tumor thickness is not a prognostic factor in thin melanoma. Archives of Dermatological Research, 279, 487–488.PubMedCrossRef

Haluska, F. G., & Ibrahim, N. (2006). Therapeutic targets in melanoma: map kinase pathway. Current Oncology Reports, 8, 400–405.PubMedCrossRef

Kalinsky, K., & Haluska, F. G. (2007). Novel inhibitors in the treatment of metastatic melanoma. Expert Review of Anticancer Therapy, 7, 715–724.PubMedCrossRef

Monzon, J., Liu, L., Brill, H., Goldstein, A. M., Tucker, M. A., From, L., et al. (1998). CDKN2A mutations in multiple primary melanomas. New England Journal of Medicine, 338, 879–887.PubMedCrossRef

Dissanayake, S. K., Wade, M. S., Johnson, C. E., O’Connell, M. P., Leotlela, P. D., French, A. D., et al. (2007). The WNT5A/PKC pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors, and initiation of an epithelial to mesenchymal transition. Journal of Biological Chemistry, 282(23), 17259–17271.PubMedCrossRef

Weeraratna, A. T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., et al. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell, 1, 279–288.PubMedCrossRef

10.

Clark, E. A., Golub, T. R., Lander, E. S., & Hynes, R. O. (2000). Genomic analysis of metastasis reveals an essential role for RhoC. Nature, 406, 532–535.PubMedCrossRef

11.

Carr, K. M., Bittner, M., & Trent, J. M. (2003). Gene-expression profiling in human cutaneous melanoma. Oncogene, 22, 3076–3080.PubMedCrossRef

12.

Cha, H. J., Jeong, M. J., & Kleinman, H. K. (2003). Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute, 95, 1674–1680.PubMed

13.

Ballweber, E., Hannappel, E., Huff, T., Stephan, H., Haener, M., Taschner, N., et al. (2002). Polymerisation of chemically cross-linked actin:thymosin beta(4) complex to filamentous actin: alteration in helical parameters and visualisation of thymosin beta(4) binding on F-actin. Journal of Molecular Biology, 315, 613–625.PubMedCrossRef

14.

Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., et al. (2000). Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature, 406, 536–540.PubMedCrossRef

15.

Jaeger, J., Koczan, D., Thiesen, H. J., Ibrahim, S. M., Gross, G., Spang, R., et al. (2007). Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clinical Cancer Research, 13, 806–815.PubMedCrossRef

16.

Winnepenninckx, V., Lazar, V., Michiels, S., Dessen, P., Stas, M., Alonso, S. R., et al. (2006). Gene expression profiling of primary cutaneous melanoma and clinical outcome. Journal of the National Cancer Institute, 98, 472–482.PubMed

17.

Haqq, C., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D., Pulliam, B. L., et al. (2005). The gene expression signatures of melanoma progression. Proceedings of the National Academy of Sciences of the United States of America, 102, 6092–6097.PubMedCrossRef

18.

Ryu, B., Kim, D. S., Deluca, A. M., & Alani, R. M. (2007). Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE, 2, e594.PubMedCrossRef

19.

Alonso, S. R., Tracey, L., Ortiz, P., Perez-Gomez, B., Palacios, J., Pollan, M., et al. (2007). A high-throughput study in melanoma identifies epithelial–mesenchymal transition as a major determinant of metastasis. Cancer Research, 67, 3450–3460.PubMedCrossRef

20.

Eguchi, T., Takaki, T., Itadani, H., & Kotani, H. (2007). RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene. Oncogene, 26, 509–520.PubMedCrossRef

21.

Saito, S., Liu, X. F., Kamijo, K., Raziuddin, R., Tatsumoto, T., Okamoto, I., et al. (2004). Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the Rho signaling pathways leading to malignant transformation. Journal of Biological Chemistry, 279, 7169–7179.PubMedCrossRef

22.

O’Brien, S. L., Fagan, A., Fox, E. J., Millikan, R. C., Culhane, A. C., Brennan, D. J., et al. (2007). CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. International Journal of Cancer, 120, 1434–1443.CrossRef

23.

Zhu, X., Mancini, M. A., Chang, K. H., Liu, C. Y., Chen, C. F., Shan, B., et al. (1995). Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression. Molecular and Cellular Biology, 15, 5017–5029.PubMed

24.

Laoukili, J., Kooistra, M. R., Bras, A., Kauw, J., Kerkhoven, R. M., Morrison, A., et al. (2005). FoxM1 is required for execution of the mitotic programme and chromosome stability. Nature Cell Biology, 7, 126–136.PubMedCrossRef

25.

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949–954.PubMedCrossRef

26.

Libra, M., Malaponte, G., Navolanic, P. M., Gangemi, P., Bevelacqua, V., Proietti, L., et al. (2005). Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle, 4, 1382–1384.PubMed

27.

Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., et al. (2003). High frequency of BRAF mutations in nevi. Nature Genetics, 33, 19–20.PubMedCrossRef

28.

Dumaz, N., Hayward, R., Martin, J., Ogilvie, L., Hedley, D., Curtin, J. A., et al. (2006). In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Research, 66, 9483–9491.PubMedCrossRef

29.

Petti, C., Molla, A., Vegetti, C., Ferrone, S., Anichini, A., & Sensi, M. (2006). Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Research, 66, 6503–6511.PubMedCrossRef

30.

Bottazzi, M. E., Zhu, X., Bohmer, R. M., & Assoian, R. K. (1999). Regulation of p21(cip1) expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in G1 phase. Journal of Cell Biology, 146, 1255–1264.PubMedCrossRef

31.

Zhu, X., Ohtsubo, M., Bohmer, R. M., Roberts, J. M., & Assoian, R. K. (1996). Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. Journal of Cell Biology, 133, 391–403.PubMedCrossRef

32.

Bhatt, K. V., Spofford, L. S., Aram, G., McMullen, M., Pumiglia, K., & Aplin, A. E. (2005). Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene, 24, 3459–3471.PubMedCrossRef

33.

Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. Journal of Experimental Medicine, 203, 1651–1656.PubMedCrossRef

34.

Byzova, T. V., Goldman, C. K., Pampori, N., Thomas, K. A., Bett, A., Shattil, S. J., et al. (2000). A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Molecular Cell, 6, 851–860.PubMed

35.

Michaloglou, C., Vredeveld, L. C., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M., et al. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature, 436, 720–724.PubMedCrossRef

36.

Gao, L., Feng, Y., Bowers, R., Becker-Hapak, M., Gardner, J., Council, L., et al. (2006). Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Research, 66, 7880–7888.PubMedCrossRef

37.

Kooistra, M. R., Dube, N., & Bos, J. L. (2007). Rap1: a key regulator in cell–cell junction formation. Journal of Cell Science, 120, 17–22.PubMedCrossRef

38.

Koistinen, P., Ahonen, M., Kahari, V. M., & Heino, J. (2004). alphaV integrin promotes in vitro and in vivo survival of cells in metastatic melanoma. International Journal of Cancer, 112, 61–70.CrossRef

39.

Huntington, J. T., Shields, J. M., Der, C. J., Wyatt, C. A., Benbow, U., & Slingluff Jr., C. L. (2004). Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. Journal of Biological Chemistry, 279, 33168–33176.PubMedCrossRef

40.

Chu, C. L., Reenstra, W. R., Orlow, D. L., & Svoboda, K. K. (2000). Erk and PI-3 kinase are necessary for collagen binding and actin reorganization in corneal epithelia. Investigative Ophthalmology and Visual Science, 41, 3374–3382.PubMed

41.

Hess, A. R., & Hendrix, M. J. (2006). Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle, 5, 478–480.PubMed

42.

Goel, V. K., Lazar, A. J., Warneke, C. L., Redston, M. S., & Haluska, F. G. (2006). Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. Journal of Investigative Dermatology, 126, 154–160.PubMedCrossRef

43.

Kim, A., Oh, J. H., Park, J. M., & Chung, A. S. (2007). Methylselenol generated from selenomethionine by methioninase downregulates integrin expression and induces caspase-mediated apoptosis of B16F10 melanoma cells. Journal of Cellular Physiology, 212, 386–400.PubMedCrossRef

44.

Smalley, K. S., Haass, N. K., Brafford, P. A., Lioni, M., Flaherty, K. T., et al. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Molecular Cancer Therapeutics, 5, 1136–1144.PubMedCrossRef

45.

Sumimoto, H., Miyagishi, M., Miyoshi, H., Yamagata, S., Shimizu, A., et al. (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene, 23, 6031–6039.PubMedCrossRef

46.

Liu, Z. J., Xiao, M., Balint, K., Smalley, K. S., Brafford, P., Qiu, R., et al. (2006). Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Research, 66, 4182–4190.PubMedCrossRef

47.

Dai, D. L., Martinka, M., & Li, G. (2005). Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. Journal of Cellular Physiology, 23, 1473–1482.

48.

Hakem, A., Sanchez-Sweatman, O., You-Ten, A., Duncan, G., Wakeham, A., Khokha, R., et al. (2005). RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes & Development, 19, 1974–1979.CrossRef

49.

Croft, D. R., Sahai, E., Mavria, G., Li, S., Tsai, J., Lee, W. M., et al. (2004). Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Research, 64, 8994–9001.PubMedCrossRef

50.

Ruth, M. C., Xu, Y., Maxwell, I. H., Ahn, N. G., Norris, D. A., & Shellman, Y. G. (2006). RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. Journal of Investigative Dermatology, 126, 862–868.PubMedCrossRef

51.

Stashl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., et al. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research, 64, 7002–7010.CrossRef

52.

Govindarajan, B., Sligh, J. E., Vincent, B. J., Li, M., Canter, J. A., Nickoloff, B. J., et al. (2007). Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. Journal of Clinical Investigation, 117, 719–729.PubMedCrossRef

53.

Kleer, C. G., Griffith, K. A., Sabel, M. S., Gallagher, G., van Golen, K. L., Wu, Z. F., et al. (2005). RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Research and Treatment, 93, 101–110.PubMedCrossRef

54.

Yao, H., Dashner, E. J., van Golen, C. M., & van Golen, K. L. (2006). RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene, 25, 2285–2296.PubMedCrossRef

55.

Shikada, Y., Yoshino, I., Okamoto, T., Fukuyama, S., Kameyama, T., & Maehara, Y. (2003). Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma. Clinical Cancer Research, 9, 5282–5286.PubMed

56.

Thiery, J. P. (2003). Epithelial-mesenchymal transitions in development and pathologies. Current Opinion in Cell Biology, 15, 740–746.PubMedCrossRef

57.

Danen, E. H., de Vries, T. J., Morandini, R., Ghanem, G. G., Ruiter, D. J., & van Muijen, G. N. (1996). E-cadherin expression in human melanoma. Melanoma Research, 6, 127–131.PubMedCrossRef

58.

Hsu, M. Y., Wheelock, M. J., Johnson, K. R., & Herlyn, M. (1996). Shifts in cadherin profiles between human normal melanocytes and melanomas. Journal of Investigative Dermatology Symposium Proceedings, 1, 188–194.

59.

Qi, J., Chen, N., Wang, J., & Siu, C. H. (2005). Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Molecular Biology of the Cell, 16, 4386–4397.PubMedCrossRef

60.

Sandig, M., Voura, E. B., Kalnins, V. I., & Siu, C. H. (1997). Role of cadherins in the transendothelial migration of melanoma cells in culture. Cell Motility and the Cytoskeleton, 38, 351–364.PubMedCrossRef

61.

Qi, J., Wang, J., Romanyuk, O., & Siu, C. H. (2006). Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Molecular Biology of the Cell, 17, 1261–1272.PubMedCrossRef

62.

Watson-Hurst, K., & Becker, D. (2006). The Role of N-Cadherin, MCAM and beta(3) integrin in melanoma progression, proliferation, migration and invasion. Cancer Biotherapy, 5, 1375–1382.

63.

Larue, L., & Delmas, V. (2006). The WNT/Beta-catenin pathway in melanoma. Frontiers in Bioscience, 11, 733–742.PubMedCrossRef

64.

Miyagishi, M., Fujii, R., Hatta, M., Yoshida, E., Araya, N., Nagafuchi, A., et al. (2000). Regulation of Lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP/p300. Journal of Biological Chemistry, 275, 35170–35175.PubMedCrossRef

65.

Nieto, M. A. (2002). The snail superfamily of zinc-finger transcription factors. Nature Reviews, Molecular Cell Biology, 3, 155–166.CrossRef

66.

Poser, I., Dominguez, D., de Herreros, A. G., Varnai, A., Buettner, R., & Bosserhoff, A. K. (2001). Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. Journal of Biological Chemistry, 276, 24661–24666.PubMedCrossRef

67.

Kippenberger, S., Loitsch, S., Thaci, D., Muller, J., Guschel, M., Kaufmann, R., et al. (2006). Restoration of E-cadherin sensitizes human melanoma cells for apoptosis. Melanoma Research, 16, 393–403.PubMedCrossRef

68.

Kuphal, S., Palm, H. G., Poser, I., & Bosserhoff, A. K. (2005). Snail-regulated genes in malignant melanoma. Melanoma Research, 15, 305–313.PubMedCrossRef

69.

Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., et al. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology, 2, 76–83.PubMedCrossRef

70.

Bienz, M. (2005). beta-Catenin: a pivot between cell adhesion and Wnt signalling. Current Biology, 15, R64–R67.PubMedCrossRef

71.

Smith, A. P., Hoek, K., & Becker, D. (2005). Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biotherapy, 4, 1018–1029.

72.

Ma, H., Nguyen, C., Lee, K. S., & Kahn, M. (2005). Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene, 24, 3619–3631.PubMedCrossRef

73.

Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 436, 117–122.PubMedCrossRef

74.

Loercher, A. E., Tank, E. M., Delston, R. B., & Harbour, J. W. (2005). MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. Journal of Cell Biology, 168, 35–40.PubMedCrossRef

75.

Levy, C., Khaled, M., & Fisher, D. E. (2006). MITF: master regulator of melanocyte development and melanoma oncogene. Trends in Molecular Medicine, 12, 406–414.PubMedCrossRef

76.

Schepsky, A., Bruser, K., Gunnarsson, G. J., Goodall, J., Hallsson, J. H., Goding, C. R., et al. (2006). The microphthalmia-associated transcription factor Mitf interacts with beta-catenin to determine target gene expression. Molecular and Cellular Biology, 26, 8914–8927.PubMedCrossRef

77.

Hemesath, T. J., Price, E. R., Takemoto, C., Badalian, T., & Fisher, D. E. (1998). MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature, 391, 298–301.PubMedCrossRef

Title: Cell cycle control and adhesion signaling pathways in the development of metastatic melanoma
Authors: A. V. Danilov
O. V. Danilova
B. T. Huber
Publication date: 01-12-2008
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9159-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

Imaging of tumor glucose utilization with positron emission tomography

Preface-imaging in cancer

Imaging of integrin αvβ3 expression

Non-invasive assessment of tumor neovasculature: techniques and clinical applications

Molecular imaging of epidermal growth factor receptor expression–activity at the kinase level in tumors with positron emission tomography

Biography - Anthony F. Shields, M.D., Ph.D.

Keynote webinar | Spotlight on antibody–drug conjugates in cancer